公开(公告)号：US11261171B1

公开(公告)日：2022-03-01

申请号：US16680969

申请日：2019-11-12

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Gianni Chessari ,  Steven Howard ,  Ildiko Maria Buck ,  Benjamin David Cons ,  Christopher Norbert Johnson ,  Rhian Sara Holvey ,  David Charles Rees ,  Jeffrey David St. Denis ,  Emiliano Tamanini ,  Bernard Thomas Golding ,  Ian Robert Hardcastle ,  Celine Florence Cano ,  Duncan Charles Miller ,  Martin Edward Mäntylä Noble ,  Roger John Griffin ,  James Daniel Osborne ,  Joanne Peach ,  Arwel Lewis ,  Kim Louise Hirst ,  Benjamin Paul Whittaker ,  David Wyn Watson ,  Dale Robert Mitchell

IPC: C07D401/06 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/501 ,  A61K31/496 ,  A61K31/4545 ,  A61K31/444 ,  A61K31/4439 ,  A61P35/00 ,  C07D417/14 ,  C07D409/14 ,  C07D407/14 ,  C07D403/06 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D403/14 ,  C07D487/04 ,  C07B59/00 ,  C07D487/08 ,  A61K45/06

Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

公开(公告)号：US12071429B2

公开(公告)日：2024-08-27

申请号：US17164045

申请日：2021-02-01

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Gianni Chessari ,  Steven Howard ,  Ildiko Maria Buck ,  Benjamin David Cons ,  Christopher Norbert Johnson ,  Rhian Sara Holvey ,  David Charles Rees ,  Jeffrey David St. Denis ,  Emiliano Tamanini ,  Bernard Thomas Golding ,  Ian Robert Hardcastle ,  Celine Florence Cano ,  Duncan Charles Miller ,  Martin Edward Mäntylä Noble ,  Roger John Griffin ,  James Daniel Osborne ,  Joanne Peach ,  Arwel Lewis ,  Kim Louise Hirst ,  Benjamin Paul Whittaker ,  David Wyn Watson ,  Dale Robert Mitchell

IPC: C07D405/14 ,  A61K31/4035 ,  A61P35/00 ,  C07D209/48 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D413/06 ,  C07D413/12 ,  C07F9/572

CPC classification number: C07D405/14 ,  A61K31/4035 ,  A61P35/00 ,  C07D209/48 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D413/06 ,  C07D413/12 ,  C07F9/5728 ,  C07B2200/05

Abstract: The invention provides a compound of formula (I):




or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims.

Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

公开(公告)号：US10981898B2

公开(公告)日：2021-04-20

申请号：US16535931

申请日：2019-08-08

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Gianni Chessari ,  Steven Howard ,  Ildiko Maria Buck ,  Benjamin David Cons ,  Christopher Norbert Johnson ,  Rhian Sara Holvey ,  David Charles Rees ,  Jeffrey David St. Denis ,  Emiliano Tamanini ,  Bernard Thomas Golding ,  Ian Robert Hardcastle ,  Celine Florence Cano ,  Duncan Charles Miller ,  Martin Edward Mäntylä Noble ,  Roger John Griffin ,  James Daniel Osborne ,  Joanne Peach ,  Arwel Lewis ,  Kim Louise Hirst ,  Benjamin Paul Whittaker ,  David Wyn Watson ,  Dale Robert Mitchell

IPC: C07D405/14 ,  C07D403/06 ,  C07D405/12 ,  C07D413/12 ,  C07D209/48 ,  C07D413/06 ,  C07D403/12 ,  C07F9/572 ,  A61P35/00

Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

公开(公告)号：US09358222B2

公开(公告)日：2016-06-07

申请号：US14085632

申请日：2013-11-20

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Bernard Thomas Golding ,  Christiane Riedinger ,  Roger John Griffin ,  Ian Robert Hardcastle ,  Eric Valeur ,  Anna Frances Watson ,  Martin Noble

IPC: C07D207/46 ,  A61K31/4035 ,  C07D209/48 ,  C07D401/06 ,  C07D403/06

CPC classification number: C07D209/49 ,  A61K31/4035 ,  A61K31/4402 ,  A61K45/06 ,  C07D209/48 ,  C07D401/06 ,  C07D403/06

Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.

公开(公告)号：US10526311B2

公开(公告)日：2020-01-07

申请号：US15763724

申请日：2016-09-29

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Gianni Chessari ,  Steven Howard ,  Ildiko Maria Buck ,  Benjamin David Cons ,  Christopher Norbert Johnson ,  Rhian Sara Holvey ,  David Charles Rees ,  Jeffrey David St. Denis ,  Emiliano Tamanini ,  Bernard Thomas Golding ,  Ian Robert Hardcastle ,  Celine Florence Cano ,  Duncan Charles Miller ,  Martin Edward Mäntylä Noble ,  Roger John Griffin ,  James Daniel Osborne ,  Joanne Peach ,  Arwel Lewis ,  Kim Louise Hirst ,  Benjamin Paul Whittaker ,  David Wyn Watson ,  Dale Robert Mitchell

IPC: C07D401/06 ,  A61K31/4439 ,  C07D401/14 ,  C07D403/06 ,  C07D407/14 ,  C07D409/14 ,  C07D417/14 ,  A61P35/00 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06

Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

公开(公告)号：US10544132B2

公开(公告)日：2020-01-28

申请号：US15763698

申请日：2016-09-29

Applicant: ASTEX THERAPEUTICS LIMITED ,  CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Gianni Chessari ,  Steven Howard ,  Ildiko Maria Buck ,  Benjamin David Cons ,  Christopher Norbert Johnson ,  Rhian Sara Holvey ,  David Charles Rees ,  Jeffrey David St. Denis ,  Emiliano Tamanini ,  Bernard Thomas Golding ,  Ian Robert Hardcastle ,  Celine Florence Cano ,  Duncan Charles Miller ,  Martin Edward Mäntylä Noble ,  Roger John Griffin ,  James Daniel Osborne ,  Joanne Peach ,  Arwel Lewis ,  Kim Louise Hirst ,  Benjamin Paul Whittaker ,  David Wyn Watson ,  Dale Robert Mitchell

IPC: C07D405/14 ,  C07D403/06 ,  C07D405/12 ,  C07D413/12 ,  C07D209/48 ,  A61P35/00

Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.

公开(公告)号：US10414726B2

公开(公告)日：2019-09-17

申请号：US15715900

申请日：2017-09-26

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Bernard Thomas Golding ,  Christiane Riedinger ,  Roger John Griffin ,  Ian Robert Hardcastle ,  Eric Valeur ,  Anna Frances Watson ,  Martin Noble

IPC: C07D209/49 ,  C07D209/48 ,  C07D401/06 ,  C07D403/06 ,  A61K31/4035 ,  A61K31/4402 ,  A61K45/06

Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.